Announcements Trials
Browse Landscape

Phase

Phase 1 6

Status

Completed 6No longer available 1

Sponsor Class

OTHER 9INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Other solid neoplasm 6

Conditions

Neoplasms 1905Breast Neoplasms 1425Carcinoma, Non-Small-Cell Lung 1178Prostatic Neoplasms 740Colorectal Neoplasms 686Neoplasm Metastasis 623Multiple Myeloma 548Melanoma 529Ovarian Neoplasms 456Lung Neoplasms 447Lymphoma, Non-Hodgkin 385Lymphoma 374Recurrence 373Leukemia, Myeloid, Acute 370Pancreatic Neoplasms 358Carcinoma, Renal Cell 339Carcinoma, Hepatocellular 286Stomach Neoplasms 281Leukemia, Lymphocytic, Chronic, B-Cell 268Lymphoma, Follicular 254Head and Neck Neoplasms 246Glioblastoma 220Leukemia 215Small Cell Lung Carcinoma 183Lymphoma, Large B-Cell, Diffuse 183Squamous Cell Carcinoma of Head and Neck 181Urinary Bladder Neoplasms 175Carcinoma 175Uterine Cervical Neoplasms 174Advanced Solid Tumors 161

Interventions

nintedanib 1avelumab 1DOXO-EMCH 1BN 80927 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Malignant Solid Tumour × Clear all
NCT02923466 2022-04-27

Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors

Vyriad, Inc.

Phase 1 Completed
76 enrolled
Other solid neoplasm

Malignant Solid Tumour

NCT01337505 2022-02-10

Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors

ImmunityBio, Inc.

Phase 1 Completed
24 enrolled
Other solid neoplasm

Malignant Solid Tumour

NCT01435096 2020-03-03

BN80927 in Patients With Advanced Malignant Solid Tumors

Ipsen

Phase 1 Completed
56 enrolled
Other solid neoplasm

Malignant Solid Tumour

NCT01598129 2016-10-24

ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers

Targovax ASA

Phase 1 Completed
12 enrolled 9 charts
Other solid neoplasm

Malignant Solid Tumour

NCT01184807 2014-03-26

Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors

Otsuka Beijing Research Institute

Phase 1 Completed
51 enrolled
Other solid neoplasm

Malignant Solid Tumour

NCT01951846 2013-09-27

To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours

Boehringer Ingelheim

Phase 1 Completed
61 enrolled
Other solid neoplasm

Malignant Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡